General Information of the Protein
Protein ID
PT00859
Protein Name
Protein-tyrosine kinase 6
Secondarily
Protein Name
Breast tumor kinase
Tyrosine-protein kinase BRK
Gene Name
PTK6
Secondarily
Gene Name
BRK
Sequence
MVSRDQAHLGPKYVGLWDFKSRTDEELSFRAGDVFHVARKEEQWWWATLLDEAGGAVAQGYVPHNYLAERETVESEPWFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKIWRRAGGRLHLNEAVSFLSLPELVNYHRAQSLSHGLRLAAPCRKHEPEPLPHWDDWERPREEFTLCRKLGSGYFGEVFEGLWKDRVQVAIKVISRDNLLHQQMLQSEIQAMKKLRHKHILALYAVVSVGDPVYIITELMAKGSLLELLRDSDEKVLPVSELLDIAWQVAEGMCYLESQNYIHRDLAARNILVGENTLCKVGDFGLARLIKEDVYLSHDHNIPYKWTAPEALSRGHYSTKSDVWSFGILLHEMFSRGQVPYPGMSNHEAFLRVDAGYRMPCPLECPPSVHKLMLTCWCRDPEQRPCFKALRERLSSFTSYENPT
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
TK protein kinase group
>
Tyrosine protein kinase Src family
Function
Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways.
    Show/Hide
Uniprot ID
Primary ID:
Q13882

Secondarily ID:
B2RCR3
B4DW46
Q58F01
    Show/Hide
Ensembl ID
ENSG00000101213
HGNC ID
HGNC:9617
Subcellular Location
Cytoplasm
Nucleus
Cell projection
Ruffle
Membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000006 , HEK293
Compound ID Compound Name Compound Formula
CP0052228
5-[(2,3-dibromo-6-hydroxy-5-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H11Br2N3O3
 1
1
IC50 = 1460 nM
   TI
   LI
   LO
   TS
CP0052456
5-[(2,3-dibromo-5-ethoxy-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H13Br2N3O3
 1
1
IC50 = 1600 nM
   TI
   LI
   LO
   TS
CP0248127
2-(1,3-benzothiazol-5-yliminomethyl)-3,4-dibromo-6-ethoxyphenol
   Show/Hide
C16H12Br2N2O2S
 1
1
IC50 = 2540 nM
   TI
   LI
   LO
   TS
CP0489414
5-[(2,3-dichloro-5-ethoxy-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H13Cl2N3O3
 1
1
IC50 = 3480 nM
   TI
   LI
   LO
   TS
CP0190556
3,4-dibromo-2-(1H-indol-5-yliminomethyl)-6-methoxyphenol
   Show/Hide
C16H12Br2N2O2
 1
1
IC50 = 3490 nM
   TI
   LI
   LO
   TS
CP0263124
2-(1,3-benzothiazol-5-yliminomethyl)-3,4-dibromo-6-methoxyphenol
   Show/Hide
C15H10Br2N2O2S
 1
1
IC50 = 4610 nM
   TI
   LI
   LO
   TS
CP0190555
2-(3H-benzimidazol-5-yliminomethyl)-3,4-dibromo-6-ethoxyphenol
   Show/Hide
C16H13Br2N3O2
 1
1
IC50 = 4710 nM
   TI
   LI
   LO
   TS
CP0261970
2-(3H-benzimidazol-5-yliminomethyl)-3,4-dibromo-6-methoxyphenol
   Show/Hide
C15H11Br2N3O2
 1
1
IC50 = 5520 nM
   TI
   LI
   LO
   TS
CP0305102
3,4-dibromo-6-ethoxy-2-(1H-indol-5-yliminomethyl)phenol
   Show/Hide
C17H14Br2N2O2
 1
1
IC50 = 7580 nM
   TI
   LI
   LO
   TS
CP0268103
5-[(2,3,5-tribromo-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H8Br3N3O2
 1
1
IC50 = 11750 nM
   TI
   LI
   LO
   TS
CP0305103
5-[(6-bromo-2-hydroxy-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12BrN3O3
 1
1
IC50 = 16630 nM
   TI
   LI
   LO
   TS
CP0366694
5-[(5-bromo-3-ethoxy-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H14BrN3O3
 1
1
IC50 = 23510 nM
   TI
   LI
   LO
   TS
CP0566554
5-[(2-bromo-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H10BrN3O2
 1
1
IC50 = 24490 nM
   TI
   LI
   LO
   TS
CP0305105
5-[(3,5-dibromo-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H9Br2N3O2
 1
1
IC50 = 48960 nM
   TI
   LI
   LO
   TS
CP0305106
5-[(5-chloro-3-ethoxy-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H14ClN3O3
 1
1
IC50 = 51250 nM
   TI
   LI
   LO
   TS
CP0263125
5-[(5-bromo-2-hydroxy-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12BrN3O3
 1
1
IC50 = 52440 nM
   TI
   LI
   LO
   TS
CP0068792
(2E)-2-[(3,4-dihydroxyphenyl)carbonyl]-3-(1H-indol-3-yl)prop-2-enenitrile
   Show/Hide
C18H12N2O3
 1
1
IC50 = 53240 nM
   TI
   LI
   LO
   TS
CP0088925
5-[(2-hydroxy-5-iodo-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12IN3O3
 1
1
IC50 = 58100 nM
   TI
   LI
   LO
   TS
CP0305107
5-[(5-chloro-2-hydroxy-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12ClN3O3
 1
1
IC50 = 74040 nM
   TI
   LI
   LO
   TS
CP0190558
5-[(5-bromo-2-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12BrN3O2
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0260177
5-[(5-chloro-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H10ClN3O2
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0305109
5-[(2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H11N3O2
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0509095
5-[(5-bromo-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H10BrN3O2
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0116655
3-(9H-pyrido[2,3-b]indol-4-ylamino)phenol
   Show/Hide
C17H13N3O
 1
1 IC50 = 3.15 nM
CP0487045
N-(3-chlorophenyl)-9H-pyrido[2,3-b]indol-4-amine
   Show/Hide
C17H12ClN3
 1
1 IC50 = 4.75 nM
CP0052228
5-[(2,3-dibromo-6-hydroxy-5-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H11Br2N3O3
 1
1 IC50 = 120 nM
CP0190555
2-(3H-benzimidazol-5-yliminomethyl)-3,4-dibromo-6-ethoxyphenol
   Show/Hide
C16H13Br2N3O2
 1
1 IC50 = 130 nM
CP0261970
2-(3H-benzimidazol-5-yliminomethyl)-3,4-dibromo-6-methoxyphenol
   Show/Hide
C15H11Br2N3O2
 1
1 IC50 = 200 nM
CP0190556
3,4-dibromo-2-(1H-indol-5-yliminomethyl)-6-methoxyphenol
   Show/Hide
C16H12Br2N2O2
 1
1 IC50 = 270 nM
CP0305102
3,4-dibromo-6-ethoxy-2-(1H-indol-5-yliminomethyl)phenol
   Show/Hide
C17H14Br2N2O2
 1
1 IC50 = 360 nM
CP0268103
5-[(2,3,5-tribromo-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H8Br3N3O2
 1
1 IC50 = 410 nM
CP0052456
5-[(2,3-dibromo-5-ethoxy-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H13Br2N3O3
 1
1 IC50 = 520 nM
CP0248127
2-(1,3-benzothiazol-5-yliminomethyl)-3,4-dibromo-6-ethoxyphenol
   Show/Hide
C16H12Br2N2O2S
 1
1 IC50 = 1170 nM
CP0489414
5-[(2,3-dichloro-5-ethoxy-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H13Cl2N3O3
 1
1 IC50 = 1290 nM
CP0263124
2-(1,3-benzothiazol-5-yliminomethyl)-3,4-dibromo-6-methoxyphenol
   Show/Hide
C15H10Br2N2O2S
 1
1 IC50 = 1300 nM
CP0566554
5-[(2-bromo-6-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H10BrN3O2
 1
1 IC50 = 1350 nM
CP0260177
5-[(5-chloro-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H10ClN3O2
 1
1 IC50 = 1410 nM
CP0305107
5-[(5-chloro-2-hydroxy-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12ClN3O3
 1
1 IC50 = 1680 nM
CP0509095
5-[(5-bromo-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H10BrN3O2
 1
1 IC50 = 1900 nM
CP0305106
5-[(5-chloro-3-ethoxy-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H14ClN3O3
 1
1 IC50 = 1990 nM
CP0305109
5-[(2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H11N3O2
 1
1 IC50 = 2000 nM
CP0068792
(2E)-2-[(3,4-dihydroxyphenyl)carbonyl]-3-(1H-indol-3-yl)prop-2-enenitrile
   Show/Hide
C18H12N2O3
 1
1 IC50 = 2320 nM
CP0305103
5-[(6-bromo-2-hydroxy-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12BrN3O3
 1
1 IC50 = 3900 nM
CP0263125
5-[(5-bromo-2-hydroxy-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12BrN3O3
 1
1 IC50 = 4730 nM
CP0088925
5-[(2-hydroxy-5-iodo-3-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12IN3O3
 1
1 IC50 = 4980 nM
CP0305105
5-[(3,5-dibromo-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C14H9Br2N3O2
 1
1 IC50 = 5600 nM
CP0366694
5-[(5-bromo-3-ethoxy-2-hydroxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C16H14BrN3O3
 1
1 IC50 = 5830 nM
CP0190558
5-[(5-bromo-2-methoxyphenyl)methylideneamino]-1,3-dihydrobenzimidazol-2-one
   Show/Hide
C15H12BrN3O2
 1
1 IC50 = 17110 nM
Clinical Information about the Protein
Target 1 ( Tyrosine-protein kinase BRK (PTK6) )
Target Type Clinical trial Target